From Molecules to Markets

From Molecules to Markets EDITORIAL Broadening the Focus of Cardiovascular Innovation See Article by Sangaralingham et al Nalini A. Colaco, MD, PhD Dhruv S. Kazi, MD, MSc, n July 7, 2015, sacubitril/valsartan became the first angiotensin receptor- MS neprilysin inhibitor approved by the US Food and Drug Administration for Ouse among patients with symptomatic heart failure with reduced ejection fraction (HFrEF). This expedited approval was based on the results of the PARA- DIGM-HF trial (Prospective Comparison of ARNI with ACE-I to Determine Impact on Global Mortality and Morbidity in Heart Failure) that showed that among pa- tients with New York Heart Association class II–IV heart failure and ejection fraction ≤40%, treatment with sacubitril/valsartan rather than 10 mg twice daily of enalapril produced a 17.7% reduction in the composite end point of cardiovascular mor- tality and hospitalizations for heart failure. The study demonstrated a remarkable 19.4% reduction in death from cardiovascular causes and 17.9% reduction in heart failure hospitalizations among patients receiving sacubitril/valsartan compared with those receiving enalapril. Sacubitril/valsartan is the first new-in-class medication to demonstrate a mortality benefit in patients with HFrEF since the early 2000s. In this issue of Circulation: Heart Failure, Sangaralingham et al describe the early experience with sacubitril/valsartan among http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Circulation: Heart Failure Wolters Kluwer Health

From Molecules to Markets

Loading next page...
 
/lp/wolters_kluwer/from-molecules-to-markets-DYoiEySHfK
Publisher
Wolters Kluwer
Copyright
© 2018 American Heart Association, Inc.
ISSN
1941-3289
eISSN
1941-3297
D.O.I.
10.1161/CIRCHEARTFAILURE.118.004815
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL Broadening the Focus of Cardiovascular Innovation See Article by Sangaralingham et al Nalini A. Colaco, MD, PhD Dhruv S. Kazi, MD, MSc, n July 7, 2015, sacubitril/valsartan became the first angiotensin receptor- MS neprilysin inhibitor approved by the US Food and Drug Administration for Ouse among patients with symptomatic heart failure with reduced ejection fraction (HFrEF). This expedited approval was based on the results of the PARA- DIGM-HF trial (Prospective Comparison of ARNI with ACE-I to Determine Impact on Global Mortality and Morbidity in Heart Failure) that showed that among pa- tients with New York Heart Association class II–IV heart failure and ejection fraction ≤40%, treatment with sacubitril/valsartan rather than 10 mg twice daily of enalapril produced a 17.7% reduction in the composite end point of cardiovascular mor- tality and hospitalizations for heart failure. The study demonstrated a remarkable 19.4% reduction in death from cardiovascular causes and 17.9% reduction in heart failure hospitalizations among patients receiving sacubitril/valsartan compared with those receiving enalapril. Sacubitril/valsartan is the first new-in-class medication to demonstrate a mortality benefit in patients with HFrEF since the early 2000s. In this issue of Circulation: Heart Failure, Sangaralingham et al describe the early experience with sacubitril/valsartan among

Journal

Circulation: Heart FailureWolters Kluwer Health

Published: Feb 1, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off